Stay up to date on all things ulcers. Sign up and we’ll send you the latest news, resources, scientific breakthroughs, events, tips, and much more.

Share this post on your profile with a comment of your own:

Successfully Shared!

View on my Profile

Changes Associated With H. Pylori and Gastric Carcinogenesis

September 9, 2019


This is a research study for patients who currently have or previously had an H. pylori infection or who have gastric or esophageal cancer and who plan to undergo an endoscopy as part of their care. The purpose of this study is to find out how and why H. pylori infections can cause progression to gastric cancer and if it’s possible to intervene prior to this progression.


Study Information

Patients with prior or current active H. pylori infection who are planning to undergo endoscopic evaluation will be eligible for participation. From these patients, up to four additional biopsies from each area of stomach already being sampled will be taken. There will also be a small subset of patients without H. pylori enrolled as well, serving as a control group. 

The biopsies will be used for next-generation RNA and DNA sequencing and analyses. The analysis will be performed at Weill Cornell Medical College by Doron Betel, PhD. The sequencing will be performed in the Epigenetics Core laboratory under the supervision of Doron Betel.

This is an observational study with approximately 120 participants. It began in July 2012 and is estimated to conclude in April 2021.


Inclusion Criteria

  • Patient must be 18 years or older
  • Patient must have active or prior H. pylori infection, or have been treated for H.pylori infection in the past, as assessed by ELISA (not applicable for the subset of patient controls) or have gastric or esophageal cancer or have Barrett’s Esophagus
  • Patients must be eligible for and are planning to undergo a routine upper endoscopy and tissue biopsy
  • Patients must sign informed consent


Exclusion Criteria

  • Prior history of upper GI bleed (within 3 months)
  • Bleeding disorder or coagulopathy
  • Recent stroke or myocardial infarction (within 3 months)



This study is taking place in the Weill Cornell Medical College in New York, United States. For further information contact Julianna Brouwer, MPH on 212-746-8539 or


Sponsors / Collaborators

This study is sponsored by the Weill Medical College of Cornell University, with Manish Shah, MD as the Principal Investigator.

Clinical Trials

View All Clinical Trials

Multi-Center Acute Severe Ulcerative Colitis Cohort Study

Over one-third of patients with ‘acute severe colitis (ASUC)’ will not respond well to the intravenous…

Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis

T cells are integral to the production and development of ulcerative colitis. GSK2831781 targets these specific T…

Low Sulfur Fecal Transplant for Ulcerative Colitis

It is currently unknown if the microorganisms (microbiota) in patients with ulcerative colitis (UC) is inherently…

Helicobacter Pylori Genome Project

Helicobacter pylori (H. pylori) is a common bacterial infection which can lead to severe stomach problems or…

Benralizumab for Eosinophilic Gastritis

This study seeks to assess the effectiveness of repeat doses of benralizumab to reduce eosinophilic inflammation in…

Outcome Measures in Eosinophilic Gastrointestinal Disorders

The aim of this study is to twofold: firstly, to find the best measures to define how well a person with…

Assessing NuShield Versus Standard of Care in Diabetic Foot Ulcers

NuShield® is a dehydrated, sterile placental allograft (donor tissue…

Send this to a friend